 | Up a level |
Rothschild, Sacha I; Kappeler, Andreas; Ratschiller, Daniel; Betticher, Daniel C; Tschan, Mario P; Gugger, Mathias; Gautschi, Oliver (2011). The stem cell gene "inhibitor of differentiation 1" (ID1) is frequently expressed in non-small cell lung cancer. Lung cancer, 71(3), pp. 306-11. Amsterdam: Elsevier 10.1016/j.lungcan.2010.06.018
Lange, Annika; Gustke, Heike; Glassmeier, Günter; Heine, Markus; Zangemeister-Wittke, Uwe; Schwarz, Jürgen R; Schumacher, Udo; Lange, Tobias (2011). Neuronal differentiation by indomethacin and IBMX inhibits proliferation of small cell lung cancer cells in vitro. Lung cancer, 74(2), pp. 178-87. Amsterdam: Elsevier 10.1016/j.lungcan.2011.03.017
Zappa, Francesco; Droege, Cornelia; Betticher, Daniel; von Moos, Roger; Bubendorf, Lukas; Ochsenbein, Adrian; Gautschi, Oliver; Oppliger Leibundgut, Elisabeth; Froesch, Patrizia; Stahel, Rolf; Hess, Thomas; Rauch, Daniel; Schmid, Petra; Mayer, Michael; Crowe, Susanne; Brauchli, Peter; Ribi, Karin; Pless, Miklos; on behalf of the Swiss Group for Clinical Cancer Research (SAKK), (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). Lung cancer, 78(3), pp. 239-44. Amsterdam: Elsevier 10.1016/S1359-6349(09)71860-9
Lammel, Verena; Stoeckle, Christina; Padberg, Barbara; Zweifel, Roland; Kienle, Dirk L; Reinhart, Walter H; Simon, Hans-Uwe (2012). Hypereosinophilia driven by GM-CSF in large-cell carcinoma of the lung. Lung cancer, 76(3), pp. 493-5. Amsterdam: Elsevier 10.1016/j.lungcan.2012.02.014
Gautschi, Oliver; Ratschiller, Daniel; Gugger, Mathias; Betticher, Daniel C; Heighway, Jim (2007). Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung cancer, 55(1), pp. 1-14. Amsterdam: Elsevier 10.1016/j.lungcan.2006.09.024
Gautschi, Oliver; Hugli, Barbara; Ziegler, Annemarie; Bigosch, Colette; Bowers, Naomi L; Ratschiller, Daniel; Jermann, Monika; Stahel, Rolf A; Heighway, Jim; Betticher, Daniel C (2006). Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung cancer, 51(3), pp. 303-11. Amsterdam: Elsevier 10.1016/j.lungcan.2005.10.025
Ziegler, Annemarie; Seemayer, Christian A; Hinterberger, Marc; Vogt, Peter; Bigosch, Colette; Gautschi, Oliver; Tornillo, Luigi; Betticher, Daniel C; Moch, Holger; Stahel, Rolf A (2007). Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results. Lung cancer, 57(3), pp. 282-91. Amsterdam: Elsevier 10.1016/j.lungcan.2007.03.025
Belyanskaya, Larisa L; Ziogas, Algirdas; Hopkins-Donaldson, Sally; Kurtz, Stefanie; Simon, Hans-Uwe; Stahel, Rolf; Zangemeister-Wittke, Uwe (2008). TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Lung cancer, 60(3), pp. 355-65. Amsterdam: Elsevier 10.1016/j.lungcan.2007.11.005
Ribi, Karin; Bernhard, Jürg; Schuller, Jan C; Weder, Walter; Bodis, Stephan; Jörger, Markus; Betticher, Daniel; Schmid, Ralph A; Stupp, Roger; Ris, Hans-Beat; Stahel, Rolf A (2008). Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung cancer, 61(3), pp. 398-404. Amsterdam: Elsevier 10.1016/j.lungcan.2008.01.013
Krause, Arthur; Roma, Luca; Lorber, Thomas; Habicht, James; Lardinois, Didier; De Filippo, Maria Rosaria; Prince, Spasenija Savic; Piscuoglio, Salvatore; Ng, Charlotte K Y; Bubendorf, Lukas (2020). Deciphering the clonal relationship between glandular and squamous components in adenosquamous carcinoma of the lung using whole exome sequencing. Lung cancer, 150, pp. 132-138. Elsevier 10.1016/j.lungcan.2020.10.013
Addeo, Alfredo; Rothschild, Sacha I; Holer, Lisa; Schneider, Martina; Waibel, Christine; Haefliger, Simon; Mark, Michael; Fernandez, Eugenio; Mach, Nicolas; Mauti, Laetitia; Jermann, Philip M; Alborelli, Ilaria; Calgua, Byron; Savic-Prince, Spasenija; Joerger, Markus; Früh, Martin (2022). Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. Lung cancer, 172, pp. 154-159. Elsevier 10.1016/j.lungcan.2022.08.016
Akram, F; Wolf, J L; Trandafir, T E; Dingemans, Anne-Marie C; Stubbs, A P; von der Thüsen, J H (2023). Artificial intelligence-based recurrence prediction outperforms classical histopathological methods in pulmonary adenocarcinoma biopsies. Lung cancer, 186(107413), p. 107413. Elsevier 10.1016/j.lungcan.2023.107413
Jörger Messerli, Marianne; Baty, F; Früh, M; Stahel, R A; Betticher, D C; von Moos, Rodica; Ochsenbein, Adrian; Pless, M; Gautschi, O; Rothschild, S; Brauchli, P; Klingbiel, Dirk; Zappa, F; Brutsche, M (2014). Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung cancer, 85(2), pp. 306-313. Elsevier 10.1016/j.lungcan.2014.04.014
Rothschild, Sacha; Gautschi, Oliver; Batliner, Jasmin; Gugger, Mathias; Fey, Martin; Tschan, Mario (2017). MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors. Lung cancer, 107, pp. 73-83. Elsevier 10.1016/j.lungcan.2016.06.004
Rieber, Juliane; Streblow, Jan; Uhlmann, Lorenz; Flentje, Michael; Duma, Marciana; Ernst, Iris; Blanck, Oliver; Wittig, Andrea; Boda-Heggemann, Judit; Krempien, Robert; Lohaus, Fabian; Klass, Natalie Désirée; Eble, Michael J; Imhoff, Detlef; Kahl, Henning; Petersen, Cordula; Gerum, Sabine; Henkenberens, Christoph; Adebahr, Sonja; Hass, Peter; ... (2016). Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy". Lung cancer, 97, pp. 51-58. Elsevier 10.1016/j.lungcan.2016.04.012
Jeremic, Branislav; Gomez-Caamano, Antonio; Dubinsky, Pavol; Cihoric, Nikola; Igrutinovic, Ivan; Videtic, Gregory (2018). Low level evidence supporting the choice of optimal multimodality treatment approach in patients with stage IIIA NSCLC- Ain't no mountain high enough…. to keep me getting to you. Lung cancer, 123, pp. 172-173. Elsevier 10.1016/j.lungcan.2018.06.016
Süveg, Krisztian; Putora, Paul Martin; Berghmans, Thierry; Glatzer, Markus; Kovac, Veljko; Cihoric, Nikola (2018). Current efforts in research of pleural mesothelioma-An analysis of the ClinicalTrials.gov registry. Lung cancer, 124, pp. 12-18. Elsevier 10.1016/j.lungcan.2018.07.007
Peters, S; Felip, E; Dafni, U; Belka, C; Guckenberger, M; Irigoyen, A; Nadal, E; Becker, Antje; Vees, H; Pless, M; Martinez-Marti, A; Tufman, A; Lambrecht, M; Andratschke, N; Piguet, A C; Kassapian, M; Roschitzki-Voser, H; Rabaglio, Manuela; Stahel, R A; Vansteenkiste, J; ... (2019). Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. Lung cancer, 133, pp. 83-87. Elsevier 10.1016/j.lungcan.2019.05.001
Früh, M.; Panje, C.M.; Reck, M; Blackhall, F; Califano, R; Cappuzzo, F; Besse, B; Novello, S; Garrido, P; Felip, E; O'Brien, M; Paz Ares, L; de Marinis, F; Westeel, V; De Ruysscher, D; Putora, P.M. (2020). Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. Lung cancer, 146, pp. 6-11. Elsevier 10.1016/j.lungcan.2020.03.024
Froesch, Patrizia; Mark, Michael; Rothschild, Sacha I; Li, Qiyu; Godar, Gilles; Rusterholz, Corinne; Oppliger Leibundgut, Elisabeth; Schmid, Sabine; Colombo, Ilaria; Metaxas, Yannis; König, David; Sessa, Cristiana; Gautschi, Oliver; Früh, Martin (2021). Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. Lung cancer, 156, pp. 91-99. Elsevier 10.1016/j.lungcan.2021.04.002
Peters, Solange; Danson, Sarah; Ejedepang, Dunson; Dafni, Urania; Hasan, Baktiar; Radcliffe, Hoi-Shen; Bustin, Frederique; Crequit, Jacky; Coate, Linda; Guillot, Monica; Surmont, Veerle; Rauch, Daniel; Rudzki, Jakob; O'Mahony, Deirdre; Barneto Aranda, Isidoro; Scherz, Amina; Tsourti, Zoi; Roschitzki-Voser, Heidi; Pochesci, Alessia; Demonty, Gaston; ... (2021). Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. Lung cancer, 161, pp. 76-85. Elsevier 10.1016/j.lungcan.2021.09.002
Schuler, A; Huser, J; Schmid, S; Schär, S; Scherz, A; Gautschi, O; Mauti, L; von Briel, T; Waibel, C; Wannesson, L; Pankovics, J; Mark, M T; Rothschild, S I; Addeo, A; Janthur, W D; Siano, M; Boos, L; Britschgi, C; Früh, M (2024). Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study. Lung cancer, 187(107427), p. 107427. Elsevier 10.1016/j.lungcan.2023.107427
